Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00324987
Show Display Options
Rank Status Study
1 Active, not recruiting Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Imatinib Mesylate;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

Indicates status has not been verified in more than two years